Clinicopathological Characteristics of Mucinous Breast Cancer: A Retrospective Analysis of a 10-Year Study

Lei Lei1☯, Xingfei Yu2☯, Bo Chen3, Zhanhong Chen1, Xiaojia Wang1*

1 Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, P. R. China, 2 Department of Breast Tumor Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, P. R. China, 3 Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, P. R. China

☯ These authors contributed equally to this work.
*
wangxj@zjcc.org.cn

Abstract

Background

Mucinous breast carcinoma (MC) is a special type of breast cancer that presents with a large amount of extracellular mucin. MC comprises approximately 4% of all invasive breast cancers. This type of tumor has a better prognosis and higher incidence in peri- and post-menopausal patients. Pathologically, there are two main subtypes of MC: pure and mixed. In this study, we describe 10 years of experience with MC at the Zhejiang Cancer Hospital in China, specifically, clinical data, histological findings and immunohistochemical features.

Methods

We identified MC patients who were diagnosed as operable and completed clinical treatment from January 2001 to January 2011. The clinicopathological data included the age at diagnosis, tumor size, TNM stage, presence and number of lymph node (LN) metastases, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) status and p53 expression. If the tumor was defined as mixed mucinous carcinoma (MMC), IHC was performed on a non-mucinous part, such as invasive ductal and lobular cancer. We evaluated the clinical characteristics of all MC patients using chi-square, one-way ANOVA and LSD tests. We also studied the correlations between all of the clinical parameters and LN metastasis in a binary logistic regression analysis. We used ten consecutive years of data that were collected at Zhejiang Cancer Hospital.

Results

We identified 48 cases of pure mucinous carcinoma (PMC) and 77 cases of MMC. The 48 PMC cases consisted of 38 PMC-A and 10 PMC-B subtypes. The MMCs were divided into two groups, those with partial mixed mucinous breast carcinoma (pMMC, 58 cases) and those with main mixed mucinous breast carcinoma (mMMC, 19 cases). pMMC was defined by tumors with less than 50% mucinous components, while mMMC was defined by tumors...
where the mucinous component accounted for 50% to 90% of the tumor. No significant differences in the clinicopathological characteristics were noted between the patients with PMC-A and those with PMC-B. The tumor size was larger in the mMMC than PMC cases (44.84 mm vs. 30.06 mm, p = 0.021). The number of positive LN metastases was greater in pMMC than PMC patients (p = 0.024). The clinical stages were significantly different among the three groups, with the pMMC group having more stage III-IV patients than the other two groups (p = 0.005). The incidence of LN metastasis was also higher in the pMMC cases (pMMC vs. mMMC and PMC, 50% vs. 31.58% and 18.75%, p = 0.003). The PMC patients had much lower p53 expression than the other two groups (PMC vs. pMMC and mMMC, 27.08% vs. 55.17% and 57.89%, p = 0.007). The incidence of LN metastasis was also higher in the pMMC cases (pMMC vs. mMMC and PMC, 50% vs. 31.58% and 18.75%, p = 0.003). The PMC patients had much lower p53 expression than the other two groups (PMC vs. pMMC and mMMC, 27.08% vs. 55.17% and 57.89%, p = 0.007). The tumor size (>30mm), p53 expression and less proportion of the mucinous component are associated with risk of LN metastasis.

Conclusion

Based on the results of this study, we conclude that the tumor size, status of LN metastasis, clinical stage, and p53 mutation rate may differ between MMC and PMC patients. The tumor size (>30mm), p53 mutation and less proportion of the mucinous component should be considered risk factors of LN metastasis in MC patients.

Introduction

Mucinous breast carcinoma (MC) is a special type of breast cancer that presents with a large amount of extracellular mucin. MC comprises approximately 4% (range: 1% to 7%) of all invasive breast cancers [1–3]. MC has a better prognosis (90% survival at 10 years) and a higher incidence in peri- and post-menopausal patients [4]. Pathologically, MC is divided into two main subtypes, pure and mixed [5]. The distinction between these subtypes is based on the quantification of cellularity. The mucinous component varies from 30% to over 90% of the tumor [6]. Currently, there is no established percentage to make a positive diagnosis of mucinous carcinoma. However, most pathologists agree that a diagnosis of pure mucinous carcinoma (PMC) should be reserved for tumors with at least 90% mucinous components [7]. The pure type almost exclusively consists of tumor tissue with extracellular mucin production, while the mixed subtype also contains other in situ or invasive components without mucin.

PMC represents approximately 2% of all malignant breast carcinomas [1]. This type of cancer is most commonly diagnosed in women aged 55–67 and above [6,8–17]. The characteristic feature of this type of cancer is that it can be diagnosed at relatively early stages of the disease. Stage T1–2 tumors are diagnosed in 75%–97% of patients, and a lack of metastases to lymph nodes is observed in 62%–88% of patients [6,11,18–23]. Usually, PMC is ER and PR positive and AR negative [8]. PMC may be subtyped into a hypocellular variant (PMC-A), showing a tubular, cribriform, cord-like, micropapillary or papillary growth pattern, and a hypercellular variant (PMC-B), growing in solid nests [24]. Conventionally, PMC exhibits a metastasis rate of less than 15% [25] and has a better prognosis than invasive breast carcinoma of no special type [2,7,26].

Mixed mucinous carcinoma (MMC) is mainly associated with lobular or ductal neoplasia (in situ or invasive), and some tumors have neuroendocrine differentiation [3]. However, a specific percentage has not been clearly established for MMC diagnosis. Due to the distinct clinicopathological parameters of PMC and MMC, there may be a prognostic difference between
the two groups. The 10-year survival rate of the pure type (90.4%) was better (p<0.001) than that of the mixed type (66.0%) [27].

The purpose of this paper is to report on 10 years of experience with MC at Zhejiang Cancer Hospital in China, specifically clinical data, histological findings and immunohistochemical features.

Ethics statement

The Zhejiang Cancer Hospital Ethic Institution Office approved this study. This retrospective study poses no potential risk to the subjects, and the subjects’ personal privacy was protected. This study strictly conforms to the principles outlined in the Declaration of Helsinki.

Materials and Methods

Patients diagnosed with PMC (Fig 1) and MMC (Fig 2) according to the WHO Classification of Tumours of the Breast 2012 [8] between 2001 and 2011 at Zhejiang Cancer Hospital in China were retrospectively included in this study. The clinicopathological data evaluated included age at diagnosis, tumor size (mm), TNM stage (AJCC 7th ed.), p53 expression, status and number of metastatic lymph nodes (LNs), and expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). The PMC patients were subtyped into PMC-A and PMC-B groups for comparison purposes. All immunohistochemical materials (i.e., HE slices, immunohistochemical staining slices and paraffin-embedded slices) were reassessed, and the findings were confirmed by professional pathologists. If the tumor was defined as MMC, IHC was performed on a non-mucinous part, such as invasive ductal and lobular cancer. ER, PR and p53 expression were measured using semi-quantitative cell nucleus scores. Cases that were 3+ by IHC or + by fluorescence in situ hybridization (FISH) were defined as HER2-positive. Cases that were IHC 1+/or FISH- were considered negative for HER2 expression. Cases with IHC 2+ were further tested by FISH to confirm HER2 status. Data collection and processing were performed using SPSS (v22.0). We used χ² tests (and Fisher’s exact test, if necessary) to analyze qualitative data. Comparisons of the age at diagnosis, tumor size and number of positive LNs among the three subgroups of MC were

![Fig 1. A 51-year-old woman with stage IIA pT2N0M0 PMC. Pathological diagnosis was made using H&E staining, which showed PMC—hypocellular variant, sparse nests or individual cells floating in a large amount of mucin, segmented by fibers. ER (3+), PR (3+), CerbB-2 (-). All images had an original magnification of ×40 and were H&E stained unless otherwise indicated. A (arrow) shows mucinous breast carcinoma. Abbreviations: H&E, hematoxylin and eosin; PMC, pure mucinous breast carcinoma; staging was performed according to the seventh edition of the TNM Classification for Breast Cancer.

doi:10.1371/journal.pone.0155132.g001]
tested by one-way ANOVA and LSD tests. Logistic regression was used in multivariate analyses to identify risk factors impacting LN metastasis. The age at diagnosis (>40y), tumor size (>30mm), ER/PR/HER-2/P53 status and subgroups of MC were included as potential risk factors. The significance level was defined as $p < 0.05$.

Results

In total, 48 patients were diagnosed with PMC, and 77 patients were diagnosed with MMC at the Zhejiang Cancer Hospital. All MC patients represented 2.4% of all (5,297) patients treated for breast cancer during this period. The 48 PMC cases consisted of 38 PMC-A and 10 PMC-B cases. No significant differences in the clinicopathological characteristics were noted between the patients with PMC-A and those with PMC-B (Table 1). The MMC patients were divided into two groups: those with partial mixed mucinous breast carcinoma (pMMC, 58 cases) and those with main mixed mucinous breast carcinoma (mMMC, 19 cases). The pMMC was defined as tumors with <50% mucinous components, and mMMC was defined as tumors where the mucinous component accounted for 50% to 90% of the tumor. The additional invasive components in MMC included infiltrative ductal breast cancer (51 cases), lobular breast cancer (two cases) and other types of breast cancer (five cases).

The mean ages of all groups were similar (pMMC vs. mMMC vs. PMC, 50.66 vs. 52.08 vs. 52.26 years, respectively, $p > 0.05$). The tumor size was larger in the mMMC than in the PMC group (44.84 mm vs. 30.06 mm, $p = 0.021$). The clinical stages were significantly different among the three groups ($p = 0.005$). The pMMC group had more stage III-IV patients than the other groups. LN metastasis was also more common in the pMMC patients (pMMC vs. mMMC and PMC, 50% vs. 31.58% and 18.75%, respectively, $p = 0.003$). The number of positive LN metastases was higher in pMMC than PMC patients ($p = 0.024$). ER positivity was found in 41 (85.41%) of the PMC cases and 66 (85.71%) of the MMC cases. PR positivity was found in 35 (72.92%) of the PMC cases and 51 (66.23%) of the MMC cases. HER-2 positivity was found in three (6.25%) of the PMC cases and 11 (14.29%) of the MMC cases. The rate of positivity for ER, PR and HER-2 was similar among the three groups ($p > 0.05$). The PMC patients had much lower p53 expression than the other two groups (PMC vs. pMMC and mMMC).
mMMC, 27.08% vs. 55.17% and 57.89%, respectively, p = 0.007) (Table 2). The tumor size (>30mm), p53 expression and subgrouping of MC according to the proportion of the mucinous component were associated with LN metastasis (Table 3).

**Discussion**

PMC represents approximately 2% of all breast cancers [8]. In comparison to infiltrating ductal carcinoma of the breast, PMC has better prognostic features. According to the literature, the 5-year and 10-year survival rates of infiltrating ductal carcinoma and PMC are 77%–92% and 75%–89% (overall), respectively, and 76%–91% and 74%–93% (disease-free), respectively [6,9,11,18–19,21,27–29]. Pathological characteristics are dominant in approximately 90%–100% of PMC cases. No significant difference in clinicopathological characteristics was noted in our study between the PMC-A and PMC-B subtypes. This result is consistent with those obtained in some previous studies [24]. Therefore, we compared the combination of PMC-A and PMC-B patients with other groups of MC. In the mixed form of MC, other invasive carcinoma components are also present.

Although an exact percentage necessary to diagnose mucinous carcinoma has not been clearly established, most pathologists agree that a diagnosis of PMC should be reserved for tumors with a mucinous component of at least 90%. It is important to clearly distinguish PMC from MMC, with the latter containing a mixture of mucinous and non-mucinous components, because the prognosis of pure mucinous carcinoma seems to be better than that of MMC [17]. In our study, MMC was sub-divided into two groups based on the mixed mucinous component. To the best of our knowledge, there is no definite cutoff in terms of the percentage for diagnosing partial or major mucinous components in MMC. However, based on our current data, MMC with a smaller mucinous component presented with worse pathological factors,
such as LN metastasis, more advanced clinical stage and higher p53 expression. These results are consistent with the clinical and immunohistochemical findings of a recent study comparing PMC with MMC [21].

Cao et al. retrospectively compared the clinical and biological features between 2,202 patients with pure invasive ductal carcinoma and 309 patients with PMC treated from 1999 to 2010 in China. They found that PMC had favorable characteristics, including a smaller tumor size, lower rates of LN positivity, lower stage, higher expression of hormone receptors, and less

Table 2. Clinical, histopathological and immunohistochemical findings of PMC in comparison with pMMC and mMMC.

| Parameters               | pMMC (N = 58) | mMMC (N = 19) | PMC (N = 48) | Significance |
|--------------------------|---------------|---------------|--------------|--------------|
| Age (years, mean±SD)     | 50.66±11.60   | 52.08±13.31   | 52.26±11.99  | F = 0.225, p = 0.799 |
| Tumor size (mm, mean±SD) | 37.84±21.70   | 44.84±32.79   | 30.06±20.80  | F* = 3.094, p* = 0.049 |
| Number of positive LN (mean±SD) | 2.90±4.95   | 0.71±2.48     | 3.26±8.36    | F# = 3.222, p# = 0.043 |
| LN status Negative       | 29            | 13            | 39           | χ² = 11.373, p = 0.003 |
| Stage                    |               |               |              | χ² = 18.773, p = 0.005 |
| I                        | 12            | 3             | 14           |               |
| II                       | 28            | 13            | 31           |               |
| III                      | 17            | 1             | 2            |               |
| IV                       | 1             | 2             | 1            |               |
| ER Negative              | 10            | 1             | 7            | χ² = 1.668, p = 0.434 |
| ER Positive              | 48            | 18            | 41           |               |
| PR Negative              | 19            | 7             | 13           | χ² = 0.726, p = 0.695 |
| PR Positive              | 39            | 12            | 35           |               |
| HER2 Negative            | 48            | 18            | 45           | χ² = 3.984, p = 0.136 |
| HER2 Positive            | 10            | 1             | 3            |               |
| p53 Negative             | 26            | 8             | 35           | χ² = 9.933, p = 0.007 |
| p53 Positive             | 32            | 11            | 13           |               |

PMC: pure mucinous breast carcinoma, mucinous component >90%; pMMC: partial mixed mucinous breast carcinoma, mucinous component <50%; mMMC: main mixed mucinous breast carcinoma, mucinous component 50%~90%.

* pMMC/mMMC, p = 0.259; pMMC/PMC, p = 0.090; mMMC/PMC, p = 0.021.

# pMMC/mMMC, p = 0.778; pMMC/PMC, p = 0.024; mMMC/PMC, p = 0.057.

Table 3. Logistic regression analysis results of factors predicting LN metastasis.

| Parameters               | B    | S.E.  | Wald  | df | Sig.  | Exp(B) | 95.0% C.I. for EXP(B) |
|--------------------------|------|-------|-------|----|-------|--------|----------------------|
|                          |      |       |       |    |       |        | Lower | Upper           |
| Age(>40y)                | -0.346| 0.609| 0.323| 1  | 0.570| 0.707  | 0.214  | 2.335           |
| Tumor size(>30mm)        | 1.731| 0.508| 11.620| 1  | 0.001| 5.648  | 2.087  | 15.281           |
| ER+                      | -0.079| 0.697| 0.013| 1  | 0.910| 0.924  | 0.236  | 3.623           |
| PR+                      | -0.366| 0.524| 0.489| 1  | 0.484| 0.693  | 0.248  | 1.937           |
| HER2+                    | 1.084| 0.761| 2.027| 1  | 0.154| 2.956  | 0.665  | 13.140           |
| P53+                     | 1.268| 0.450| 7.959| 1  | 0.005| 3.554  | 1.473  | 8.578           |
| Subgroups of MC§         | -0.425| 0.258| 2.850| 1  | 0.046| 0.847  | 0.391  | 0.972           |
| Constant                 | -2.911| 1.514| 3.697| 1  | 0.055| 0.054  |         |                 |

§ Subgroups of MC: pMMC, mMMC and PMC groups.

doi:10.1371/journal.pone.0155132.l002

doi:10.1371/journal.pone.0155132.l003
HER2 overexpression\cite{23}. In our study, the smaller tumor size, lower rate of LN metastasis and lower stage were consistent with their results. However, the ER/PR/HER2 status was not significantly different among the three groups. This may be explained by the fact that the diagnostic standards for pathological studies changed several times during the study period.

According to previous data, local and distant failures in patients with mucinous breast cancer are rare and occur in fewer than 6\% of patients \cite{6,11,22}. Diab et al. and Vo et al. claim that the decisive risk factor for the development of these failures is the presence of LN metastases \cite{9,11}. The inclusion of tumor size in the staging system may not be a significant factor, because mucin comprises the majority of the tumor volume \cite{30}. Furthermore, as was indicated by Vo et al., failures are less frequently noted in patients with MC in comparison with other histological types of breast cancer \cite{11}. In our study, we found that LN metastases and clinical stage were related to the extent of the mucinous component in MC. A smaller mucinous component corresponded to more lymph node metastases and worse clinical staging.

Erhan et al. \cite{21} noted that MMC also displayed higher p53 expression than PMC (30\% vs. 8\%; p<0.05). HER2 positive status was noted in 42\% of the MMC cases, a ratio that was higher than that in PMC (4\%; p<0.001). Our study supported the findings by Erhan et al. and also found that p53 expression was different among the three groups and corresponded to the size of the mucinous component.

However, some proliferation-related markers, such as Ki-67 and Topo II, were not regularly tested in our center until 2008. We chose 50\% as a cutoff percentage for diagnosing partial or major mucinous components in MMC according to clinical practice. More studies are warranted to determine a precise definition of partial or major mucinous components in MMC.

**Conclusion**

Based on the results from this study, we conclude that the tumor size, status of LN metastasis, clinical stage, and p53 mutation rate may differ between MMC and PMC patients. The tumor size (>30mm), p53 mutation and less proportion of the mucinous component should be considered risk factors of LN metastasis in MC patients.

**Acknowledgments**

This work was funded by the Zhejiang Province Medical Science Fund Project of China (No. 2015KYB052) and the Zhejiang Province Medical Science Research Foundation of China (Nos. 2015PYA001, 2009A030, and 2008B022).

**Author Contributions**

Conceived and designed the experiments: LL XFY XJW. Performed the experiments: LL XFY ZHC. Analyzed the data: LL. Contributed reagents/materials/analysis tools: BC ZHC XJW. Wrote the paper: LL XFY.

**References**

1. Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2004; 13: 1128–1135. PMID: 15247123

2. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008; 111: 541–547. doi: 10.1007/s10549-007-9809-z PMID: 18026874

3. Park S, Koo J, Kim JH, Yang WI, Park BW, Lee KS. Clinicopathological characteristics of mucinous carcinoma of the breast in Korea: comparison with invasive ductal carcinoma-not otherwise specified. J Korean Med Sci. 2010; 25: 361–368. doi: 10.3346/jkms.2010.25.3.361 PMID: 20191033
4. Li CI. Risk of mortality by histologic type of breast cancer in the United States. Horm. Cancer. 2010; 1: 156–165. doi: 10.1007/s12672-010-0016-8 PMID: 21761358

5. Bae SY, Choi MY, Cho DH, Lee JE, Nam SJ, Yang JH. Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathological characteristics and prognosis. J Breast Cancer. 2011; 14: 308–313. doi: 10.4048/jbc.2011.14.4.308 PMID: 22323918

6. Sas-Korczyńska B, Mitus J, Stelmach A, Ryś J, Majczyk A. Mucinous breast cancer—clinical characteristics and treatment results in patients treated at the Oncology Centre in Kraków between 1952 and 2002 Contemp Oncol (Poln). 2014; 18: 120–123. doi: 10.5114/wo.2014.42727

7. Hanagiri T, Ono K, Baba T, So T, Yamasaki M, Nagata Y, et al. Clinicopathologic characteristics of mucinous carcinoma of the breast. Int Surg. 2010; 95: 126–129. PMID: 20718318

8. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours of the breast. In: World Health Organization classification of tumours. 4th ed. Lyon: International Agency for Research on Cancer; 2012 pp. 60–61.

9. Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999; 17: 1442–1448. PMID: 10334529

10. Thurman SA, Schnitt SJ, Connolly JL, Gelman R, Harris JR, et al. Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma. Int J Radiat Oncol Biol Phys. 2004; 59: 152–159. doi: 10.1016/j.ijrobp.2003.10.029 PMID: 15093911

11. Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF, et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007; 194: 527–531. doi: 10.1016/j.amjsurg.2007.06.012 PMID: 17826073

12. Reimer T. Management of rare histological types of breast. Breast Care (Basel). 2008; 3: 190–196.

13. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005; 93: 1046–1052. doi: 10.1038/sj.bjc.6602787 PMID: 16175185

14. Karan B, Pourbagher A, Bolat FA. Unusual malignant breast lesions: imaging-pathological correlations. Diagn Interv Radiol. 2012; 18: 270–276. doi: 10.4261/1059-3872.2012.4454-11.2 PMID: 21949695

15. Cytry A, Andreiuolo F, Azoulay S, Baileyguier C, Bourgier C, Mazouni C, et al. Pure and mixed mucinous carcinoma of the breast: fine needle aspiration cytology findings and review of the literature. Cytopathology. 2013; 24: 377–384. doi: 10.1111/cyt.12016 PMID: 22994403

16. Laucirica R, Bentz JS, Khalbuss WE, Clayton AC, Souers RJ, Moriarty AT. Performance characteristics of mucinous (colloid) carcinoma of the breast in fine-needle aspirates: observations from the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytopathology. Arch Pathol Lab Med. 2011; 135: 1533–1538. doi: 10.5858/arpa.2010-0652-CP PMID: 22129179

17. Dimitr A, Procop A, Iliesiu A, Tampa M, Mitrache L, Costache M, et al. Mucinous breast cancer: a review study of 5 year experience from a hospital-based series of cases Maedica (Buchar). 2015; 10: 14–18.

18. Alijarrah A, Al-Hashmi M, Malik KA, Sukhpals S, Hussein S, Al-Riyami M, et al. Mucinous breast cancer with solitary metastasis to humeral head: a case report. Oman Med J. 2013; 28: 350–353. doi: 10.5001/omj.2013.100 PMID: 24044063

19. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008; 111: 541–547. doi: 10.1007/s10549-007-9809-z PMID: 18026874

20. Hanagiri T, Ono K, Baba T, So T, Yamasaki M, Nagata Y, et al. Clinicopathologic characteristics of mucinous carcinoma of the breast. Int Surg. 2010; 95: 126–129. PMID: 20718318
25. Ranade A, Batra R, Sandhu G, Chitale RA, Balderacchi J. Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micropapillary pattern. J Clin Pathol. 2010; 63: 1043–1047. doi: 10.1136/jcp.2010.082495 PMID: 20962055

26. André S, Cunha F, Bernardo M, Meneses e Sousa J, Cortez F, Soares J. Mucinous carcinoma of the breast: a pathologic study of 82 cases. J Surg Oncol. 1995; 58: 162–167. doi: 10.1002/jso.2930580305 PMID: 7898111

27. Komaki K, Sakamoto G, Sugano H, Morimoto T, Monden Y. Mucinous carcinoma of the breast in Japan. A prognostic analysis based on morphologic features. Cancer. 1988; 61: 989–996. doi: 10.1002/1097-0142(19880301)61:5<989::AID-CNCR2820610522>3.0.CO;2-E PMID: 2827884

28. Dhillon R, Depree P, Metcalf C, Wylie E. Screen-detected mucinous breast carcinoma: potential for delayed diagnosis. Clin Radiol. 2006; 61: 423–430. doi: 10.1016/j.crad.2005.10.008 PMID: 16679116

29. Tan JZ, Waugh J, Kumar B, Evans J. Mucinous carcinomas of the breast: imaging features and potential for misdiagnosis. J Med Imaging Radiat Oncol. 2013; 57: 25–31. doi: 10.1111/1754-9485.12006 PMID: 23374550

30. Capella C, Eusebi V, Mann B, Azzopardi JG. Endocrine differentiation in mucoïd carcinoma of the breast. Histopathology. 1980; 4: 613–630. doi: 10.1111/j.1365-2559.1980.tb02957.x PMID: 6254868